Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics
YMAB Price/Volume Stats
| Current price | $7.08 | 52-week high | $10.95 |
| Prev. close | $6.85 | 52-week low | $2.70 |
| Day low | $6.90 | Volume | 211,800 |
| Day high | $7.31 | Avg. volume | 367,907 |
| 50-day MA | $5.50 | Dividend yield | N/A |
| 200-day MA | $5.96 | Market Cap | 308.84M |
YMAB Stock Price Chart Interactive Chart >
YMAB POWR Grades
- Value is the dimension where YMAB ranks best; there it ranks ahead of 91.17% of US stocks.
- YMAB's strongest trending metric is Stability; it's been moving up over the last 177 days.
- YMAB ranks lowest in Momentum; there it ranks in the 4th percentile.
YMAB Stock Summary
- For YMAB, its debt to operating expenses ratio is greater than that reported by only 5.84% of US equities we're observing.
- With a year-over-year growth in debt of -26.86%, Y-MABS THERAPEUTICS INC's debt growth rate surpasses only 12.19% of about US stocks.
- As for revenue growth, note that YMAB's revenue has grown 113.97% over the past 12 months; that beats the revenue growth of 95.73% of US companies in our set.
- Stocks that are quantitatively similar to YMAB, based on their financial statements, market capitalization, and price volatility, are VYNE, GNTX, MVIS, HLTH, and VERU.
- YMAB's SEC filings can be seen here. And to visit Y-MABS THERAPEUTICS INC's official web site, go to www.ymabs.com.
YMAB Valuation Summary
- YMAB's price/sales ratio is 2.5; this is 34.21% lower than that of the median Healthcare stock.
- Over the past 63 months, YMAB's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for YMAB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| YMAB | 2023-11-20 | 2.5 | 2.3 | -11.9 | -6.1 |
| YMAB | 2023-11-17 | 2.5 | 2.4 | -12.3 | -6.4 |
| YMAB | 2023-11-16 | 2.5 | 2.3 | -11.9 | -6.1 |
| YMAB | 2023-11-15 | 2.5 | 2.3 | -11.9 | -6.1 |
| YMAB | 2023-11-14 | 2.5 | 2.3 | -12.1 | -6.3 |
| YMAB | 2023-11-13 | 2.3 | 2.1 | -11.0 | -5.4 |
YMAB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- YMAB has a Quality Grade of C, ranking ahead of 28.99% of graded US stocks.
- YMAB's asset turnover comes in at 0.183 -- ranking 204th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows YMAB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.183 | 0.992 | -10.948 |
| 2021-03-31 | 0.146 | 0.996 | -77.742 |
| 2020-12-31 | 0.130 | 1.000 | 45.423 |
| 2020-09-30 | 0.000 | NA | 33.823 |
| 2020-06-30 | 0.000 | NA | 26.410 |
| 2020-03-31 | 0.000 | NA | 20.272 |
YMAB Price Target
For more insight on analysts targets of YMAB, see our YMAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $55.00 | Average Broker Recommendation | 1.36 (Strong Buy) |
Y-mAbs Therapeutics, Inc. (YMAB) Company Bio
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.
Latest YMAB News From Around the Web
Below are the latest news stories about Y-MABS THERAPEUTICS INC that investors may wish to consider to help them evaluate YMAB as an investment opportunity.
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics IncY-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call TranscriptY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today’s event is being recorded. At this time, all participants are in a listen-only mode. Instructions for the question-and-answer session will follow after the prepared remarks. […] |
Q3 2023 Y-mAbs Therapeutics Inc Earnings CallQ3 2023 Y-mAbs Therapeutics Inc Earnings Call |
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational StreamliningQ3 2023 Earnings Highlight Robust Sales and Extended Cash Runway |
YMAB Price Returns
| 1-mo | 40.20% |
| 3-mo | 36.94% |
| 6-mo | -19.27% |
| 1-year | 62.39% |
| 3-year | -86.37% |
| 5-year | -67.77% |
| YTD | 45.08% |
| 2022 | -69.90% |
| 2021 | -67.26% |
| 2020 | 58.43% |
| 2019 | 53.64% |
| 2018 | N/A |
Loading social stream, please wait...